Patrick Johnston
Concepts (729)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, Large B-Cell, Diffuse | 59 | 2026 | 192 | 11.540 |
Why?
| | Lymphoma, Non-Hodgkin | 38 | 2026 | 124 | 6.970 |
Why?
| | Hematopoietic Stem Cell Transplantation | 35 | 2026 | 675 | 5.040 |
Why?
| | Visual Perception | 7 | 2025 | 183 | 3.170 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 47 | 2026 | 1953 | 3.140 |
Why?
| | Transplantation, Autologous | 34 | 2026 | 290 | 3.080 |
Why?
| | Lymphoma | 18 | 2024 | 232 | 2.670 |
Why?
| | Immunotherapy, Adoptive | 23 | 2026 | 337 | 2.480 |
Why?
| | Hodgkin Disease | 18 | 2026 | 171 | 2.370 |
Why?
| | Salvage Therapy | 13 | 2024 | 162 | 2.320 |
Why?
| | Lymphoma, B-Cell | 16 | 2026 | 132 | 2.270 |
Why?
| | Neoplasm Recurrence, Local | 25 | 2026 | 1137 | 2.160 |
Why?
| | Antigens, CD19 | 12 | 2024 | 129 | 2.140 |
Why?
| | Central Nervous System Neoplasms | 11 | 2026 | 173 | 2.140 |
Why?
| | Reaction Time | 6 | 2025 | 438 | 1.840 |
Why?
| | Visual Cortex | 2 | 2025 | 84 | 1.620 |
Why?
| | Rituximab | 28 | 2025 | 209 | 1.430 |
Why?
| | Lymphoma, Follicular | 13 | 2025 | 56 | 1.410 |
Why?
| | Biological Products | 9 | 2023 | 252 | 1.170 |
Why?
| | Aged | 122 | 2026 | 25913 | 1.150 |
Why?
| | Everolimus | 11 | 2018 | 111 | 1.050 |
Why?
| | Adult | 128 | 2026 | 40449 | 1.040 |
Why?
| | Middle Aged | 132 | 2026 | 35875 | 1.040 |
Why?
| | Humans | 235 | 2026 | 144759 | 1.000 |
Why?
| | Retrospective Studies | 63 | 2026 | 17066 | 0.940 |
Why?
| | Male | 152 | 2026 | 72315 | 0.940 |
Why?
| | Granulocyte Colony-Stimulating Factor | 5 | 2021 | 89 | 0.920 |
Why?
| | Aged, 80 and over | 61 | 2026 | 8265 | 0.920 |
Why?
| | Young Adult | 55 | 2026 | 14105 | 0.900 |
Why?
| | Lymphocytes | 9 | 2026 | 382 | 0.890 |
Why?
| | Evoked Potentials | 4 | 2025 | 128 | 0.880 |
Why?
| | Female | 145 | 2026 | 78271 | 0.870 |
Why?
| | Prognosis | 45 | 2026 | 4282 | 0.800 |
Why?
| | Disease-Free Survival | 29 | 2023 | 769 | 0.800 |
Why?
| | Monocytes | 9 | 2019 | 538 | 0.740 |
Why?
| | Antineoplastic Agents | 18 | 2021 | 2194 | 0.720 |
Why?
| | Photic Stimulation | 5 | 2025 | 264 | 0.710 |
Why?
| | Attention | 2 | 2025 | 457 | 0.710 |
Why?
| | Waldenstrom Macroglobulinemia | 5 | 2023 | 19 | 0.700 |
Why?
| | Fluorodeoxyglucose F18 | 8 | 2024 | 156 | 0.700 |
Why?
| | Peripheral Blood Stem Cell Transplantation | 10 | 2015 | 35 | 0.700 |
Why?
| | Lymphocyte Count | 17 | 2022 | 164 | 0.690 |
Why?
| | Sirolimus | 6 | 2015 | 281 | 0.680 |
Why?
| | Recurrence | 17 | 2024 | 1135 | 0.670 |
Why?
| | Lymphoma, Mantle-Cell | 6 | 2022 | 32 | 0.670 |
Why?
| | Electroencephalography | 6 | 2025 | 532 | 0.660 |
Why?
| | Brain Mapping | 6 | 2022 | 536 | 0.660 |
Why?
| | Cyclophosphamide | 15 | 2025 | 266 | 0.660 |
Why?
| | Radiopharmaceuticals | 6 | 2021 | 194 | 0.630 |
Why?
| | Multiple Myeloma | 7 | 2023 | 291 | 0.600 |
Why?
| | Neurotoxicity Syndromes | 4 | 2023 | 38 | 0.590 |
Why?
| | Treatment Outcome | 41 | 2026 | 11679 | 0.590 |
Why?
| | Doxorubicin | 13 | 2025 | 397 | 0.570 |
Why?
| | Retinal Neoplasms | 5 | 2018 | 37 | 0.560 |
Why?
| | Retinal Detachment | 6 | 2009 | 72 | 0.560 |
Why?
| | Vincristine | 11 | 2025 | 140 | 0.560 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 5 | 2021 | 76 | 0.550 |
Why?
| | Survival Rate | 21 | 2021 | 2089 | 0.530 |
Why?
| | Spatial Processing | 1 | 2017 | 1 | 0.520 |
Why?
| | Neoplasms, Second Primary | 2 | 2017 | 100 | 0.500 |
Why?
| | Positron-Emission Tomography | 7 | 2024 | 323 | 0.500 |
Why?
| | Prednisone | 10 | 2025 | 221 | 0.490 |
Why?
| | Time Perception | 1 | 2017 | 33 | 0.490 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 11 | 2017 | 97 | 0.480 |
Why?
| | Combined Modality Therapy | 9 | 2024 | 1266 | 0.470 |
Why?
| | Brain | 7 | 2021 | 2933 | 0.470 |
Why?
| | Methotrexate | 4 | 2025 | 240 | 0.460 |
Why?
| | Transplantation Conditioning | 10 | 2015 | 186 | 0.450 |
Why?
| | Cell Transformation, Neoplastic | 5 | 2019 | 339 | 0.450 |
Why?
| | Drug Resistance, Neoplasm | 8 | 2025 | 881 | 0.440 |
Why?
| | Face | 1 | 2016 | 173 | 0.440 |
Why?
| | Stem Cell Transplantation | 7 | 2021 | 191 | 0.440 |
Why?
| | Antibodies, Monoclonal | 9 | 2017 | 1519 | 0.440 |
Why?
| | Vitreous Body | 7 | 2018 | 117 | 0.430 |
Why?
| | Piperidines | 5 | 2022 | 217 | 0.430 |
Why?
| | Survival Analysis | 19 | 2021 | 1382 | 0.420 |
Why?
| | Autografts | 6 | 2022 | 55 | 0.410 |
Why?
| | Antineoplastic Agents, Immunological | 3 | 2021 | 199 | 0.410 |
Why?
| | Follow-Up Studies | 24 | 2025 | 5408 | 0.400 |
Why?
| | Synovial Cyst | 1 | 2013 | 4 | 0.390 |
Why?
| | Positron Emission Tomography Computed Tomography | 4 | 2023 | 117 | 0.380 |
Why?
| | Amyloidosis | 4 | 2018 | 44 | 0.370 |
Why?
| | Pyrimidines | 6 | 2025 | 532 | 0.370 |
Why?
| | Antigens, CD20 | 5 | 2017 | 35 | 0.360 |
Why?
| | Wrist | 1 | 2013 | 60 | 0.360 |
Why?
| | Pyrazoles | 5 | 2022 | 509 | 0.360 |
Why?
| | Lymphoma, B-Cell, Marginal Zone | 3 | 2022 | 19 | 0.360 |
Why?
| | Fingers | 1 | 2013 | 107 | 0.360 |
Why?
| | Radioimmunotherapy | 4 | 2017 | 22 | 0.350 |
Why?
| | Lymphoma, T-Cell | 3 | 2015 | 29 | 0.330 |
Why?
| | Eye Neoplasms | 5 | 2014 | 30 | 0.320 |
Why?
| | Protein-Tyrosine Kinases | 3 | 2009 | 433 | 0.310 |
Why?
| | Adolescent | 34 | 2026 | 22428 | 0.310 |
Why?
| | Orthopedic Procedures | 1 | 2013 | 243 | 0.310 |
Why?
| | Lasers, Solid-State | 1 | 2009 | 22 | 0.290 |
Why?
| | Neoplasm Proteins | 4 | 2019 | 442 | 0.290 |
Why?
| | Burkitt Lymphoma | 3 | 2022 | 62 | 0.290 |
Why?
| | Neoplasm Staging | 12 | 2020 | 1462 | 0.280 |
Why?
| | Cataract Extraction | 2 | 2009 | 119 | 0.280 |
Why?
| | Molecular Targeted Therapy | 2 | 2010 | 432 | 0.280 |
Why?
| | Magnetic Resonance Imaging | 10 | 2026 | 3863 | 0.280 |
Why?
| | Kaplan-Meier Estimate | 12 | 2018 | 965 | 0.270 |
Why?
| | Risk Factors | 23 | 2022 | 10779 | 0.270 |
Why?
| | Thalidomide | 3 | 2018 | 43 | 0.270 |
Why?
| | Killer Cells, Natural | 4 | 2023 | 467 | 0.260 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 4 | 2018 | 139 | 0.260 |
Why?
| | Dexamethasone | 6 | 2022 | 372 | 0.260 |
Why?
| | Hematopoietic Stem Cell Mobilization | 3 | 2012 | 27 | 0.250 |
Why?
| | Pattern Recognition, Visual | 2 | 2025 | 105 | 0.250 |
Why?
| | Lymphoma, T-Cell, Peripheral | 2 | 2024 | 20 | 0.240 |
Why?
| | Transfusion Reaction | 1 | 2006 | 63 | 0.240 |
Why?
| | Castleman Disease | 1 | 2026 | 16 | 0.240 |
Why?
| | TOR Serine-Threonine Kinases | 4 | 2017 | 449 | 0.240 |
Why?
| | Chemoradiotherapy | 2 | 2021 | 237 | 0.230 |
Why?
| | Fracture Fixation | 1 | 2006 | 79 | 0.230 |
Why?
| | Circulating Tumor DNA | 1 | 2026 | 43 | 0.230 |
Why?
| | Hip Fractures | 1 | 2006 | 84 | 0.230 |
Why?
| | RNA, Small Interfering | 2 | 2007 | 635 | 0.230 |
Why?
| | Peripheral Nervous System Neoplasms | 1 | 2025 | 19 | 0.230 |
Why?
| | Event-Related Potentials, P300 | 1 | 2025 | 15 | 0.220 |
Why?
| | Adaptation, Physiological | 2 | 2022 | 570 | 0.220 |
Why?
| | Eye Injuries | 3 | 1991 | 53 | 0.220 |
Why?
| | Central Nervous System | 3 | 2023 | 281 | 0.220 |
Why?
| | Thrombocytopenia | 3 | 2022 | 205 | 0.220 |
Why?
| | B-Lymphocytes | 6 | 2023 | 876 | 0.220 |
Why?
| | Medical Oncology | 2 | 2026 | 332 | 0.210 |
Why?
| | Skin Neoplasms | 2 | 2022 | 847 | 0.210 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 1 | 2024 | 29 | 0.210 |
Why?
| | Acute Kidney Injury | 2 | 2022 | 865 | 0.210 |
Why?
| | Perioperative Care | 1 | 2006 | 231 | 0.210 |
Why?
| | Appendicitis | 1 | 2026 | 148 | 0.210 |
Why?
| | Mediastinal Neoplasms | 1 | 2024 | 51 | 0.210 |
Why?
| | Conditioning, Classical | 2 | 2022 | 120 | 0.210 |
Why?
| | Cancer Vaccines | 1 | 2025 | 160 | 0.200 |
Why?
| | Hepatitis A | 1 | 2024 | 25 | 0.200 |
Why?
| | Multiprotein Complexes | 3 | 2017 | 172 | 0.200 |
Why?
| | Aqueous Humor | 2 | 2014 | 38 | 0.200 |
Why?
| | Incidence | 9 | 2024 | 2879 | 0.200 |
Why?
| | Fear | 2 | 2022 | 366 | 0.200 |
Why?
| | Orientation | 1 | 2023 | 50 | 0.190 |
Why?
| | Immunoglobulin kappa-Chains | 2 | 2014 | 23 | 0.190 |
Why?
| | Hydroxamic Acids | 2 | 2014 | 94 | 0.190 |
Why?
| | Standard of Care | 4 | 2025 | 80 | 0.190 |
Why?
| | Predictive Value of Tests | 11 | 2018 | 2115 | 0.190 |
Why?
| | Immunologic Factors | 3 | 2014 | 255 | 0.190 |
Why?
| | Prospective Studies | 15 | 2025 | 7990 | 0.190 |
Why?
| | Extinction, Psychological | 2 | 2022 | 92 | 0.190 |
Why?
| | Venous Thromboembolism | 2 | 2022 | 324 | 0.190 |
Why?
| | Cell- and Tissue-Based Therapy | 4 | 2024 | 80 | 0.190 |
Why?
| | Cerebellum | 2 | 2017 | 223 | 0.190 |
Why?
| | Facial Expression | 1 | 2023 | 74 | 0.180 |
Why?
| | Vitamin D Deficiency | 2 | 2017 | 186 | 0.180 |
Why?
| | Tomography, X-Ray Computed | 4 | 2016 | 2730 | 0.180 |
Why?
| | Yttrium Radioisotopes | 4 | 2017 | 64 | 0.180 |
Why?
| | Electromyography | 1 | 2024 | 415 | 0.180 |
Why?
| | Carmustine | 2 | 2020 | 52 | 0.180 |
Why?
| | Brain Diseases | 1 | 2023 | 152 | 0.180 |
Why?
| | Transcription Factors | 1 | 2010 | 1741 | 0.180 |
Why?
| | Myeloid Differentiation Factor 88 | 2 | 2019 | 114 | 0.180 |
Why?
| | Bortezomib | 4 | 2018 | 55 | 0.170 |
Why?
| | Immunoglobulin Light Chains | 3 | 2013 | 51 | 0.170 |
Why?
| | Status Epilepticus | 1 | 2022 | 56 | 0.170 |
Why?
| | Facial Recognition | 1 | 2022 | 35 | 0.170 |
Why?
| | Cohort Studies | 13 | 2026 | 5960 | 0.170 |
Why?
| | Magnesium Deficiency | 1 | 2021 | 2 | 0.170 |
Why?
| | Central Nervous System Diseases | 1 | 2022 | 74 | 0.170 |
Why?
| | Hypoalbuminemia | 1 | 2021 | 28 | 0.170 |
Why?
| | Measles virus | 3 | 2010 | 21 | 0.170 |
Why?
| | Fluorine Radioisotopes | 1 | 2021 | 13 | 0.170 |
Why?
| | Immunoconjugates | 1 | 2022 | 132 | 0.170 |
Why?
| | Space Perception | 1 | 2021 | 83 | 0.170 |
Why?
| | Bacterial Infections | 1 | 2023 | 246 | 0.160 |
Why?
| | Magnesium | 1 | 2021 | 155 | 0.160 |
Why?
| | Autism Spectrum Disorder | 2 | 2017 | 412 | 0.160 |
Why?
| | Vision, Ocular | 1 | 2020 | 47 | 0.160 |
Why?
| | Cytokines | 4 | 2021 | 2061 | 0.160 |
Why?
| | Antigens, CD34 | 2 | 2010 | 88 | 0.160 |
Why?
| | Schizophrenia | 2 | 2017 | 446 | 0.160 |
Why?
| | Medication Systems | 1 | 2000 | 3 | 0.160 |
Why?
| | Testis | 1 | 2021 | 163 | 0.160 |
Why?
| | Autoimmunity | 2 | 2018 | 926 | 0.160 |
Why?
| | Molecular Epidemiology | 2 | 2017 | 73 | 0.160 |
Why?
| | Filgrastim | 2 | 2017 | 13 | 0.160 |
Why?
| | Heterocyclic Compounds | 2 | 2012 | 23 | 0.160 |
Why?
| | Retinal Perforations | 3 | 1996 | 18 | 0.160 |
Why?
| | Lymphopenia | 2 | 2010 | 65 | 0.150 |
Why?
| | Automation | 1 | 2000 | 102 | 0.150 |
Why?
| | Leukemia, B-Cell | 1 | 2019 | 12 | 0.150 |
Why?
| | Melphalan | 4 | 2017 | 42 | 0.150 |
Why?
| | Nursing Staff | 1 | 2000 | 41 | 0.150 |
Why?
| | Leg | 1 | 2021 | 239 | 0.150 |
Why?
| | Drug Administration Schedule | 8 | 2017 | 779 | 0.150 |
Why?
| | Cost-Benefit Analysis | 1 | 2022 | 634 | 0.150 |
Why?
| | Proportional Hazards Models | 7 | 2023 | 1325 | 0.150 |
Why?
| | Protein Kinase Inhibitors | 4 | 2019 | 969 | 0.150 |
Why?
| | Recombinant Proteins | 3 | 2017 | 1370 | 0.150 |
Why?
| | Enterocolitis, Necrotizing | 2 | 2010 | 41 | 0.150 |
Why?
| | Cues | 1 | 2021 | 326 | 0.150 |
Why?
| | Infusions, Parenteral | 1 | 2018 | 41 | 0.140 |
Why?
| | Time Factors | 12 | 2019 | 7173 | 0.140 |
Why?
| | Leukocyte Count | 3 | 2014 | 316 | 0.140 |
Why?
| | Vidarabine | 4 | 2017 | 32 | 0.140 |
Why?
| | Mental Recall | 1 | 2020 | 222 | 0.140 |
Why?
| | Janus Kinase 1 | 1 | 2018 | 26 | 0.140 |
Why?
| | Child | 16 | 2026 | 22633 | 0.140 |
Why?
| | Myeloid-Derived Suppressor Cells | 1 | 2019 | 72 | 0.140 |
Why?
| | Autistic Disorder | 2 | 2011 | 211 | 0.140 |
Why?
| | Drug Approval | 2 | 2010 | 89 | 0.130 |
Why?
| | Thrombosis | 1 | 2022 | 393 | 0.130 |
Why?
| | Mutation, Missense | 1 | 2019 | 340 | 0.130 |
Why?
| | Leukapheresis | 2 | 2016 | 27 | 0.130 |
Why?
| | Northern Ireland | 5 | 2009 | 12 | 0.130 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2018 | 108 | 0.130 |
Why?
| | Contingent Negative Variation | 1 | 2017 | 9 | 0.130 |
Why?
| | Immunoglobulin lambda-Chains | 2 | 2014 | 9 | 0.130 |
Why?
| | Postoperative Complications | 2 | 2006 | 2919 | 0.130 |
Why?
| | Immunotherapy | 2 | 2019 | 653 | 0.130 |
Why?
| | Waste Disposal, Fluid | 1 | 2017 | 53 | 0.130 |
Why?
| | Delay Discounting | 1 | 2017 | 29 | 0.130 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2017 | 87 | 0.130 |
Why?
| | Visual Fields | 2 | 2017 | 115 | 0.130 |
Why?
| | Evoked Potentials, Visual | 1 | 2017 | 42 | 0.130 |
Why?
| | Immunophenotyping | 2 | 2015 | 322 | 0.120 |
Why?
| | Fluorouracil | 2 | 2016 | 235 | 0.120 |
Why?
| | Maximum Tolerated Dose | 4 | 2019 | 212 | 0.120 |
Why?
| | Tarsal Coalition | 1 | 2016 | 1 | 0.120 |
Why?
| | Subtalar Joint | 1 | 2016 | 5 | 0.120 |
Why?
| | Evoked Potentials, Auditory | 1 | 2017 | 180 | 0.120 |
Why?
| | Magnetoencephalography | 1 | 2017 | 160 | 0.120 |
Why?
| | Visual Acuity | 4 | 1996 | 489 | 0.120 |
Why?
| | Glycine | 1 | 2017 | 187 | 0.120 |
Why?
| | Case-Control Studies | 6 | 2021 | 3604 | 0.120 |
Why?
| | Time-to-Treatment | 1 | 2018 | 243 | 0.120 |
Why?
| | Body Fluids | 1 | 1996 | 70 | 0.110 |
Why?
| | Uveitis | 2 | 2014 | 148 | 0.110 |
Why?
| | Mental Processes | 1 | 2015 | 38 | 0.110 |
Why?
| | Biomarkers | 6 | 2023 | 4271 | 0.110 |
Why?
| | Odds Ratio | 4 | 2018 | 1075 | 0.110 |
Why?
| | Dendritic Cells | 1 | 2019 | 499 | 0.110 |
Why?
| | Myelodysplastic Syndromes | 1 | 2017 | 147 | 0.110 |
Why?
| | Antipsychotic Agents | 1 | 2017 | 213 | 0.110 |
Why?
| | Hemangioma, Capillary | 1 | 1995 | 14 | 0.110 |
Why?
| | Outpatients | 1 | 2018 | 442 | 0.110 |
Why?
| | Lymphoma, Large-Cell, Immunoblastic | 1 | 2014 | 1 | 0.110 |
Why?
| | Comprehension | 1 | 2017 | 180 | 0.110 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 257 | 0.110 |
Why?
| | Folic Acid | 1 | 2016 | 199 | 0.110 |
Why?
| | United States | 6 | 2025 | 15966 | 0.110 |
Why?
| | Psychotic Disorders | 1 | 2017 | 186 | 0.110 |
Why?
| | Environmental Monitoring | 1 | 2017 | 377 | 0.110 |
Why?
| | Boronic Acids | 2 | 2014 | 37 | 0.110 |
Why?
| | Polyethylene Glycols | 2 | 2017 | 654 | 0.110 |
Why?
| | Interleukin-10 | 2 | 2013 | 309 | 0.110 |
Why?
| | Translocation, Genetic | 2 | 2022 | 115 | 0.110 |
Why?
| | Obsessive-Compulsive Disorder | 1 | 2015 | 58 | 0.100 |
Why?
| | Optic Disk | 1 | 1995 | 53 | 0.100 |
Why?
| | Task Performance and Analysis | 1 | 2015 | 198 | 0.100 |
Why?
| | Water Pollutants, Chemical | 1 | 2017 | 234 | 0.100 |
Why?
| | Prefrontal Cortex | 1 | 2017 | 328 | 0.100 |
Why?
| | Biomarkers, Tumor | 4 | 2013 | 1313 | 0.100 |
Why?
| | Neoplasms | 2 | 2022 | 2875 | 0.100 |
Why?
| | Myeloid Cells | 1 | 2015 | 148 | 0.100 |
Why?
| | Pyrazines | 2 | 2014 | 92 | 0.100 |
Why?
| | Autoimmune Diseases | 2 | 2018 | 463 | 0.100 |
Why?
| | Feasibility Studies | 2 | 2016 | 1095 | 0.100 |
Why?
| | Heart Atria | 1 | 2014 | 144 | 0.100 |
Why?
| | Polyneuropathies | 1 | 2013 | 57 | 0.100 |
Why?
| | Intestinal Neoplasms | 1 | 2013 | 30 | 0.100 |
Why?
| | Indoles | 2 | 2014 | 501 | 0.100 |
Why?
| | Intestinal Perforation | 1 | 2013 | 44 | 0.100 |
Why?
| | Tachycardia, Supraventricular | 1 | 2013 | 45 | 0.100 |
Why?
| | Oligodeoxyribonucleotides | 1 | 2013 | 141 | 0.100 |
Why?
| | Retinal Neovascularization | 1 | 1993 | 29 | 0.090 |
Why?
| | Quality Assurance, Health Care | 2 | 2008 | 340 | 0.090 |
Why?
| | Remission Induction | 4 | 2017 | 307 | 0.090 |
Why?
| | T-Lymphocytes | 3 | 2018 | 1982 | 0.090 |
Why?
| | POEMS Syndrome | 1 | 2012 | 3 | 0.090 |
Why?
| | Peripheral Nerves | 1 | 2013 | 72 | 0.090 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2014 | 264 | 0.090 |
Why?
| | Scleral Diseases | 1 | 1992 | 2 | 0.090 |
Why?
| | Anti-Bacterial Agents | 2 | 2023 | 1907 | 0.090 |
Why?
| | Hematologic Neoplasms | 2 | 2013 | 161 | 0.090 |
Why?
| | Disease Progression | 6 | 2021 | 2847 | 0.090 |
Why?
| | Cell Proliferation | 3 | 2015 | 2496 | 0.090 |
Why?
| | Carbonated Beverages | 1 | 1991 | 16 | 0.090 |
Why?
| | Corneal Diseases | 1 | 1992 | 46 | 0.090 |
Why?
| | Attitude of Health Personnel | 1 | 2000 | 1185 | 0.090 |
Why?
| | Epidermolysis Bullosa Dystrophica | 1 | 1992 | 42 | 0.090 |
Why?
| | Child, Preschool | 6 | 2026 | 11787 | 0.090 |
Why?
| | Soft Tissue Neoplasms | 1 | 2013 | 127 | 0.090 |
Why?
| | Gene Expression Profiling | 2 | 2011 | 1782 | 0.080 |
Why?
| | Sensitivity and Specificity | 4 | 2026 | 1985 | 0.080 |
Why?
| | Stomach Neoplasms | 1 | 2013 | 126 | 0.080 |
Why?
| | Contrast Media | 2 | 2026 | 488 | 0.080 |
Why?
| | Disease Management | 2 | 2026 | 645 | 0.080 |
Why?
| | Oncolytic Virotherapy | 1 | 2010 | 13 | 0.080 |
Why?
| | Blast Injuries | 1 | 1991 | 63 | 0.080 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2022 | 240 | 0.080 |
Why?
| | Oncolytic Viruses | 1 | 2010 | 8 | 0.080 |
Why?
| | Gene Targeting | 1 | 2010 | 82 | 0.080 |
Why?
| | Samarium | 1 | 2010 | 1 | 0.080 |
Why?
| | Myeloablative Agonists | 1 | 2010 | 23 | 0.080 |
Why?
| | Radioisotopes | 1 | 2010 | 33 | 0.080 |
Why?
| | Cornea | 1 | 1992 | 155 | 0.080 |
Why?
| | X-Ray Intensifying Screens | 1 | 2010 | 3 | 0.080 |
Why?
| | Miosis | 1 | 1990 | 4 | 0.080 |
Why?
| | Arrhythmias, Cardiac | 1 | 2013 | 361 | 0.080 |
Why?
| | Gray Matter | 1 | 2011 | 91 | 0.080 |
Why?
| | Self Report | 1 | 2015 | 872 | 0.080 |
Why?
| | Short Bowel Syndrome | 1 | 2010 | 27 | 0.080 |
Why?
| | Immunosuppressive Agents | 1 | 2015 | 846 | 0.080 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2017 | 682 | 0.080 |
Why?
| | Surveys and Questionnaires | 3 | 2022 | 6048 | 0.080 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2014 | 1455 | 0.080 |
Why?
| | Holidays | 1 | 2009 | 8 | 0.080 |
Why?
| | Child Development Disorders, Pervasive | 1 | 2010 | 62 | 0.080 |
Why?
| | Indomethacin | 1 | 1990 | 76 | 0.080 |
Why?
| | Radiometry | 1 | 2010 | 56 | 0.080 |
Why?
| | Minnesota | 4 | 2013 | 169 | 0.080 |
Why?
| | Oxazines | 1 | 2009 | 37 | 0.080 |
Why?
| | Iris Diseases | 1 | 1989 | 7 | 0.080 |
Why?
| | Electronics | 1 | 2010 | 71 | 0.080 |
Why?
| | Interleukin-15 | 1 | 2010 | 97 | 0.080 |
Why?
| | Subtraction Technique | 1 | 2009 | 26 | 0.080 |
Why?
| | Uveal Neoplasms | 1 | 1989 | 16 | 0.080 |
Why?
| | Pain Threshold | 1 | 2009 | 73 | 0.080 |
Why?
| | Severity of Illness Index | 4 | 2015 | 2925 | 0.070 |
Why?
| | Organophosphorus Compounds | 1 | 2010 | 85 | 0.070 |
Why?
| | Organometallic Compounds | 1 | 2010 | 112 | 0.070 |
Why?
| | Lenses, Intraocular | 1 | 1989 | 49 | 0.070 |
Why?
| | Quinolones | 1 | 2011 | 201 | 0.070 |
Why?
| | Fatigue | 2 | 2024 | 366 | 0.070 |
Why?
| | Radiation Dosage | 1 | 2010 | 192 | 0.070 |
Why?
| | Chromosomes, Human, Pair 6 | 1 | 2008 | 46 | 0.070 |
Why?
| | Multivariate Analysis | 5 | 2012 | 1539 | 0.070 |
Why?
| | Marijuana Abuse | 1 | 2011 | 211 | 0.070 |
Why?
| | Double-Blind Method | 3 | 2019 | 2029 | 0.070 |
Why?
| | Neurons | 2 | 2009 | 1640 | 0.070 |
Why?
| | Treatment Failure | 2 | 2024 | 365 | 0.070 |
Why?
| | Hospitalization | 1 | 2018 | 2433 | 0.070 |
Why?
| | Amygdala | 1 | 2009 | 198 | 0.070 |
Why?
| | Vancomycin Resistance | 1 | 2007 | 16 | 0.070 |
Why?
| | Gases | 1 | 1988 | 53 | 0.070 |
Why?
| | Fluorescein Angiography | 3 | 1996 | 189 | 0.070 |
Why?
| | Ambulatory Surgical Procedures | 1 | 2008 | 80 | 0.070 |
Why?
| | Down-Regulation | 2 | 2007 | 627 | 0.070 |
Why?
| | Ophthalmoplegia | 1 | 1987 | 13 | 0.070 |
Why?
| | Enterococcus | 1 | 2007 | 22 | 0.070 |
Why?
| | Germinal Center | 1 | 2008 | 67 | 0.070 |
Why?
| | Torticollis | 1 | 1987 | 17 | 0.070 |
Why?
| | Obesity | 1 | 2021 | 3077 | 0.070 |
Why?
| | Cytarabine | 3 | 2017 | 66 | 0.070 |
Why?
| | Chromosomes, Human, Pair 2 | 1 | 2007 | 28 | 0.070 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 2007 | 28 | 0.070 |
Why?
| | Rhinoplasty | 1 | 2008 | 37 | 0.060 |
Why?
| | Models, Neurological | 1 | 2009 | 254 | 0.060 |
Why?
| | Logistic Models | 4 | 2018 | 2117 | 0.060 |
Why?
| | Infant, Premature, Diseases | 1 | 2008 | 111 | 0.060 |
Why?
| | Proto-Oncogene Proteins c-bcl-6 | 2 | 2022 | 11 | 0.060 |
Why?
| | Carrier State | 1 | 2007 | 79 | 0.060 |
Why?
| | Temporal Lobe | 2 | 2022 | 104 | 0.060 |
Why?
| | Emotions | 2 | 2023 | 578 | 0.060 |
Why?
| | Atrial Fibrillation | 1 | 2013 | 550 | 0.060 |
Why?
| | Immunohistochemistry | 5 | 2012 | 1716 | 0.060 |
Why?
| | Vitamin D | 1 | 2010 | 400 | 0.060 |
Why?
| | Ki-1 Antigen | 1 | 2006 | 7 | 0.060 |
Why?
| | Flow Cytometry | 4 | 2015 | 1173 | 0.060 |
Why?
| | Prosthesis Implantation | 1 | 2008 | 153 | 0.060 |
Why?
| | Diagnosis, Differential | 2 | 2026 | 1489 | 0.060 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2009 | 459 | 0.060 |
Why?
| | Radiotherapy Dosage | 2 | 2021 | 289 | 0.060 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 2006 | 55 | 0.060 |
Why?
| | Seat Belts | 1 | 1986 | 23 | 0.060 |
Why?
| | Eye | 1 | 2007 | 109 | 0.060 |
Why?
| | Quality of Life | 3 | 2023 | 3185 | 0.060 |
Why?
| | Behavior, Animal | 1 | 2009 | 519 | 0.060 |
Why?
| | Reproducibility of Results | 4 | 2015 | 3409 | 0.060 |
Why?
| | Cerebral Cortex | 1 | 2009 | 464 | 0.060 |
Why?
| | ROC Curve | 2 | 2023 | 614 | 0.060 |
Why?
| | Lymphocyte Depletion | 1 | 2006 | 132 | 0.060 |
Why?
| | Lens, Crystalline | 1 | 1987 | 136 | 0.060 |
Why?
| | Hematopoietic Stem Cells | 2 | 2010 | 420 | 0.060 |
Why?
| | Anemia | 2 | 2018 | 188 | 0.060 |
Why?
| | Neoplasm, Residual | 1 | 2026 | 139 | 0.060 |
Why?
| | Signal Transduction | 2 | 2010 | 5226 | 0.060 |
Why?
| | Pyridines | 1 | 2009 | 605 | 0.060 |
Why?
| | Isoquinolines | 1 | 2025 | 44 | 0.060 |
Why?
| | Retreatment | 2 | 2017 | 77 | 0.060 |
Why?
| | Melanoma | 2 | 1989 | 761 | 0.060 |
Why?
| | Risk Assessment | 4 | 2018 | 3671 | 0.060 |
Why?
| | Amyloid | 1 | 2006 | 92 | 0.060 |
Why?
| | Cross Infection | 1 | 2007 | 262 | 0.050 |
Why?
| | Pregnanolone | 1 | 2005 | 35 | 0.050 |
Why?
| | Neoplasm Grading | 2 | 2018 | 307 | 0.050 |
Why?
| | Induction Chemotherapy | 1 | 2025 | 87 | 0.050 |
Why?
| | Cisplatin | 2 | 2022 | 334 | 0.050 |
Why?
| | Cognition | 2 | 2024 | 1266 | 0.050 |
Why?
| | Thiophenes | 1 | 2025 | 128 | 0.050 |
Why?
| | Algorithms | 1 | 2012 | 1837 | 0.050 |
Why?
| | Vitrectomy | 2 | 2013 | 73 | 0.050 |
Why?
| | Aminopterin | 1 | 2024 | 3 | 0.050 |
Why?
| | Glaucoma | 1 | 1987 | 250 | 0.050 |
Why?
| | Regression Analysis | 1 | 2006 | 1003 | 0.050 |
Why?
| | Proteins | 1 | 2010 | 1021 | 0.050 |
Why?
| | Psychiatric Status Rating Scales | 2 | 2017 | 541 | 0.050 |
Why?
| | Apoptosis | 2 | 2015 | 2430 | 0.050 |
Why?
| | Biopsy | 2 | 2019 | 1075 | 0.050 |
Why?
| | Area Under Curve | 2 | 2017 | 330 | 0.050 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2024 | 126 | 0.050 |
Why?
| | Acute Disease | 1 | 2026 | 1030 | 0.050 |
Why?
| | Anger | 1 | 2023 | 60 | 0.050 |
Why?
| | HLA-DR Antigens | 1 | 2023 | 220 | 0.050 |
Why?
| | Lactate Dehydrogenases | 1 | 2022 | 6 | 0.050 |
Why?
| | Risk | 3 | 2010 | 911 | 0.050 |
Why?
| | Statistics, Nonparametric | 2 | 2017 | 427 | 0.050 |
Why?
| | Thymidylate Synthase | 1 | 2002 | 13 | 0.050 |
Why?
| | Syndrome | 1 | 2023 | 380 | 0.050 |
Why?
| | Creatine Kinase | 1 | 2022 | 72 | 0.050 |
Why?
| | Cell Line, Tumor | 2 | 2007 | 3540 | 0.050 |
Why?
| | Patient Selection | 1 | 2006 | 719 | 0.040 |
Why?
| | Agraphia | 1 | 2021 | 1 | 0.040 |
Why?
| | Body Weight | 2 | 2021 | 976 | 0.040 |
Why?
| | Organ Size | 2 | 2014 | 463 | 0.040 |
Why?
| | Gene Expression Regulation | 1 | 2011 | 2608 | 0.040 |
Why?
| | Ki-67 Antigen | 1 | 2002 | 117 | 0.040 |
Why?
| | Hematologic Diseases | 2 | 2014 | 66 | 0.040 |
Why?
| | Pain | 3 | 2014 | 779 | 0.040 |
Why?
| | L-Lactate Dehydrogenase | 2 | 2013 | 115 | 0.040 |
Why?
| | Confusion | 1 | 2021 | 30 | 0.040 |
Why?
| | Aphasia | 1 | 2021 | 24 | 0.040 |
Why?
| | Wounds and Injuries | 1 | 2009 | 956 | 0.040 |
Why?
| | Uric Acid | 1 | 2022 | 166 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2006 | 1053 | 0.040 |
Why?
| | Cell Cycle Proteins | 1 | 2005 | 628 | 0.040 |
Why?
| | DNA-Binding Proteins | 1 | 2008 | 1499 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2022 | 167 | 0.040 |
Why?
| | Glass | 2 | 2009 | 46 | 0.040 |
Why?
| | Stem Cells | 1 | 2005 | 626 | 0.040 |
Why?
| | Galvanic Skin Response | 1 | 2020 | 26 | 0.040 |
Why?
| | Radiotherapy | 1 | 2021 | 206 | 0.040 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2021 | 322 | 0.040 |
Why?
| | Serum Albumin | 1 | 2021 | 147 | 0.040 |
Why?
| | Electroshock | 1 | 2020 | 145 | 0.040 |
Why?
| | Creatinine | 1 | 2022 | 506 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2022 | 348 | 0.040 |
Why?
| | Manitoba | 1 | 2000 | 4 | 0.040 |
Why?
| | Benzylamines | 2 | 2012 | 43 | 0.040 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2023 | 668 | 0.040 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2026 | 985 | 0.040 |
Why?
| | Transplantation, Homologous | 2 | 2013 | 415 | 0.040 |
Why?
| | Colonic Neoplasms | 1 | 2002 | 259 | 0.040 |
Why?
| | Age Factors | 2 | 2021 | 3333 | 0.040 |
Why?
| | Vinblastine | 1 | 2019 | 75 | 0.040 |
Why?
| | Dacarbazine | 1 | 2019 | 100 | 0.040 |
Why?
| | Vero Cells | 2 | 2010 | 84 | 0.040 |
Why?
| | Medication Errors | 1 | 2000 | 83 | 0.040 |
Why?
| | Neoplasm Invasiveness | 1 | 2021 | 508 | 0.040 |
Why?
| | Amino Acid Substitution | 1 | 2019 | 304 | 0.040 |
Why?
| | Administration, Oral | 2 | 2012 | 847 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2023 | 672 | 0.040 |
Why?
| | Gamma Rays | 1 | 2018 | 56 | 0.040 |
Why?
| | Cluster Analysis | 2 | 2014 | 521 | 0.040 |
Why?
| | Intravitreal Injections | 1 | 2018 | 71 | 0.040 |
Why?
| | Immunoglobulin G | 1 | 2023 | 893 | 0.040 |
Why?
| | Injections, Intravenous | 1 | 2018 | 200 | 0.040 |
Why?
| | Aging | 1 | 2009 | 1966 | 0.030 |
Why?
| | Blotting, Western | 2 | 2015 | 1187 | 0.030 |
Why?
| | Hospitals, Teaching | 1 | 2018 | 119 | 0.030 |
Why?
| | Chi-Square Distribution | 2 | 2010 | 529 | 0.030 |
Why?
| | Anthracyclines | 1 | 2018 | 47 | 0.030 |
Why?
| | Seizures | 1 | 2022 | 460 | 0.030 |
Why?
| | Brain Neoplasms | 1 | 2007 | 1318 | 0.030 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2002 | 529 | 0.030 |
Why?
| | Bleomycin | 1 | 2019 | 253 | 0.030 |
Why?
| | Nursing Homes | 1 | 2000 | 172 | 0.030 |
Why?
| | Water Movements | 1 | 2017 | 29 | 0.030 |
Why?
| | Bendamustine Hydrochloride | 1 | 2017 | 17 | 0.030 |
Why?
| | Plasma Exchange | 1 | 2017 | 18 | 0.030 |
Why?
| | United Kingdom | 1 | 2018 | 338 | 0.030 |
Why?
| | Organoplatinum Compounds | 1 | 2017 | 66 | 0.030 |
Why?
| | Etoposide | 2 | 2008 | 166 | 0.030 |
Why?
| | Infant | 3 | 2024 | 10034 | 0.030 |
Why?
| | Immunoglobulin M | 1 | 2018 | 284 | 0.030 |
Why?
| | Rain | 1 | 2017 | 49 | 0.030 |
Why?
| | Cell Count | 2 | 2009 | 320 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2011 | 2027 | 0.030 |
Why?
| | Cell Separation | 2 | 2010 | 307 | 0.030 |
Why?
| | Animals | 8 | 2015 | 38058 | 0.030 |
Why?
| | Green Fluorescent Proteins | 2 | 2010 | 405 | 0.030 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 2017 | 99 | 0.030 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2017 | 161 | 0.030 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2011 | 758 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2022 | 916 | 0.030 |
Why?
| | Image Processing, Computer-Assisted | 2 | 2011 | 780 | 0.030 |
Why?
| | Neutropenia | 1 | 2017 | 155 | 0.030 |
Why?
| | Blood-Retinal Barrier | 1 | 1996 | 12 | 0.030 |
Why?
| | von Hippel-Lindau Disease | 1 | 1996 | 12 | 0.030 |
Why?
| | Particle Size | 1 | 2017 | 411 | 0.030 |
Why?
| | Retina | 1 | 2018 | 324 | 0.030 |
Why?
| | Fundus Oculi | 1 | 1996 | 89 | 0.030 |
Why?
| | Acoustic Stimulation | 1 | 2017 | 333 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2017 | 421 | 0.030 |
Why?
| | Registries | 2 | 2017 | 2385 | 0.030 |
Why?
| | Functional Neuroimaging | 1 | 2015 | 60 | 0.030 |
Why?
| | Extracellular Space | 1 | 1996 | 120 | 0.030 |
Why?
| | Models, Theoretical | 1 | 2018 | 582 | 0.030 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 1 | 2015 | 63 | 0.030 |
Why?
| | Foot | 1 | 2016 | 100 | 0.030 |
Why?
| | Cross-Sectional Studies | 2 | 2017 | 5868 | 0.030 |
Why?
| | Adenine | 1 | 2017 | 339 | 0.030 |
Why?
| | France | 1 | 2014 | 40 | 0.030 |
Why?
| | Ankle Joint | 1 | 2016 | 122 | 0.030 |
Why?
| | Analysis of Variance | 2 | 2009 | 1306 | 0.030 |
Why?
| | Anxiety | 1 | 2022 | 1109 | 0.030 |
Why?
| | Clone Cells | 1 | 2014 | 266 | 0.030 |
Why?
| | Polyradiculoneuropathy | 1 | 2013 | 4 | 0.030 |
Why?
| | Paraneoplastic Syndromes, Nervous System | 1 | 2013 | 14 | 0.030 |
Why?
| | Mitral Valve Insufficiency | 1 | 2014 | 72 | 0.030 |
Why?
| | Immune Reconstitution Inflammatory Syndrome | 1 | 2013 | 20 | 0.030 |
Why?
| | Ambulatory Care | 1 | 2018 | 600 | 0.030 |
Why?
| | Guillain-Barre Syndrome | 1 | 2013 | 22 | 0.030 |
Why?
| | Transfection | 2 | 2006 | 940 | 0.020 |
Why?
| | Sciatic Nerve | 1 | 2013 | 59 | 0.020 |
Why?
| | Immunoassay | 1 | 2014 | 109 | 0.020 |
Why?
| | Survival | 1 | 2013 | 38 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2015 | 1047 | 0.020 |
Why?
| | Tumor Cells, Cultured | 1 | 2015 | 919 | 0.020 |
Why?
| | Lymphatic Metastasis | 1 | 2014 | 333 | 0.020 |
Why?
| | Patient Reported Outcome Measures | 1 | 2017 | 488 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 2013 | 200 | 0.020 |
Why?
| | Device Removal | 1 | 2014 | 143 | 0.020 |
Why?
| | In Situ Hybridization | 1 | 2013 | 319 | 0.020 |
Why?
| | Medical Records | 1 | 2013 | 187 | 0.020 |
Why?
| | Vision, Binocular | 1 | 1993 | 47 | 0.020 |
Why?
| | Heart Valve Prosthesis | 1 | 2014 | 134 | 0.020 |
Why?
| | Psychomotor Performance | 1 | 2015 | 328 | 0.020 |
Why?
| | Plasmacytoma | 1 | 2012 | 19 | 0.020 |
Why?
| | Brachytherapy | 1 | 2013 | 134 | 0.020 |
Why?
| | Transcription, Genetic | 2 | 2011 | 1496 | 0.020 |
Why?
| | Neuropsychological Tests | 1 | 2017 | 1134 | 0.020 |
Why?
| | Horner Syndrome | 1 | 1992 | 7 | 0.020 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 2014 | 197 | 0.020 |
Why?
| | False Positive Reactions | 1 | 2012 | 121 | 0.020 |
Why?
| | Gastrointestinal Diseases | 1 | 2014 | 216 | 0.020 |
Why?
| | Research Design | 1 | 2018 | 1135 | 0.020 |
Why?
| | Explosions | 1 | 1991 | 15 | 0.020 |
Why?
| | Costs and Cost Analysis | 1 | 2012 | 219 | 0.020 |
Why?
| | Hippocampus | 2 | 2009 | 965 | 0.020 |
Why?
| | Farnesyltranstransferase | 1 | 2011 | 21 | 0.020 |
Why?
| | Diagnostic Imaging | 1 | 2014 | 338 | 0.020 |
Why?
| | Food Labeling | 1 | 1991 | 13 | 0.020 |
Why?
| | Diagnostic Techniques, Ophthalmological | 1 | 2011 | 53 | 0.020 |
Why?
| | Immunologic Techniques | 1 | 2011 | 38 | 0.020 |
Why?
| | Tomography, Optical Coherence | 1 | 2013 | 271 | 0.020 |
Why?
| | Interleukin-1beta | 1 | 2013 | 395 | 0.020 |
Why?
| | Databases, Factual | 1 | 2017 | 1486 | 0.020 |
Why?
| | RNA Splicing Factors | 1 | 2011 | 64 | 0.020 |
Why?
| | Blood Viscosity | 1 | 2010 | 18 | 0.020 |
Why?
| | Iowa | 1 | 2010 | 32 | 0.020 |
Why?
| | Psychometrics | 1 | 2015 | 734 | 0.020 |
Why?
| | Plasmapheresis | 1 | 2010 | 22 | 0.020 |
Why?
| | Phosphorylation | 1 | 2015 | 1732 | 0.020 |
Why?
| | Secondary Prevention | 1 | 2012 | 254 | 0.020 |
Why?
| | Intelligence Tests | 1 | 2010 | 56 | 0.020 |
Why?
| | Gastrointestinal Tract | 1 | 2013 | 208 | 0.020 |
Why?
| | Prostaglandin Antagonists | 1 | 1990 | 3 | 0.020 |
Why?
| | Cells, Cultured | 2 | 2010 | 4154 | 0.020 |
Why?
| | Drug Therapy, Combination | 2 | 2010 | 1047 | 0.020 |
Why?
| | Silicon | 1 | 2010 | 22 | 0.020 |
Why?
| | Early Medical Intervention | 1 | 2010 | 61 | 0.020 |
Why?
| | Transplantation Chimera | 1 | 2010 | 56 | 0.020 |
Why?
| | Frontal Lobe | 1 | 2011 | 160 | 0.020 |
Why?
| | Syk Kinase | 1 | 2009 | 22 | 0.020 |
Why?
| | Exons | 1 | 2011 | 358 | 0.020 |
Why?
| | Cannabinoid Receptor Antagonists | 1 | 2009 | 1 | 0.020 |
Why?
| | Receptors, Cannabinoid | 1 | 2009 | 14 | 0.020 |
Why?
| | Accidents, Home | 1 | 2009 | 33 | 0.020 |
Why?
| | Administration, Topical | 1 | 1990 | 150 | 0.020 |
Why?
| | Poisson Distribution | 1 | 2009 | 78 | 0.020 |
Why?
| | Boston | 1 | 2009 | 92 | 0.020 |
Why?
| | Equipment Failure Analysis | 1 | 2010 | 128 | 0.020 |
Why?
| | Tissue Distribution | 1 | 2010 | 327 | 0.020 |
Why?
| | Ophthalmic Solutions | 1 | 1990 | 79 | 0.020 |
Why?
| | Medulla Oblongata | 1 | 2009 | 37 | 0.020 |
Why?
| | Mice, SCID | 1 | 2010 | 369 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2010 | 284 | 0.020 |
Why?
| | Inflammation | 1 | 2021 | 2878 | 0.020 |
Why?
| | Periaqueductal Gray | 1 | 2009 | 37 | 0.020 |
Why?
| | Lacerations | 1 | 2009 | 40 | 0.020 |
Why?
| | Formaldehyde | 1 | 2009 | 66 | 0.020 |
Why?
| | Endophthalmitis | 1 | 1989 | 45 | 0.020 |
Why?
| | Random Allocation | 1 | 1990 | 363 | 0.020 |
Why?
| | Tumor Burden | 1 | 2010 | 319 | 0.020 |
Why?
| | White Matter | 1 | 2011 | 153 | 0.020 |
Why?
| | Morpholines | 1 | 2009 | 128 | 0.020 |
Why?
| | Macular Edema | 1 | 1989 | 49 | 0.020 |
Why?
| | Catheters, Indwelling | 1 | 2009 | 96 | 0.020 |
Why?
| | Vision Disorders | 1 | 1991 | 178 | 0.020 |
Why?
| | Aminopyridines | 1 | 2009 | 127 | 0.020 |
Why?
| | Cataract | 1 | 1992 | 238 | 0.020 |
Why?
| | Atrophy | 1 | 2009 | 201 | 0.020 |
Why?
| | Alternative Splicing | 1 | 2011 | 247 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-fos | 1 | 2009 | 196 | 0.020 |
Why?
| | Prevalence | 1 | 2016 | 2834 | 0.020 |
Why?
| | Rats | 2 | 2009 | 5597 | 0.020 |
Why?
| | Intraoperative Complications | 1 | 1990 | 155 | 0.020 |
Why?
| | Bone Marrow | 1 | 2010 | 304 | 0.020 |
Why?
| | Diarrhea | 1 | 2009 | 192 | 0.020 |
Why?
| | Sulfur Hexafluoride | 1 | 1988 | 2 | 0.020 |
Why?
| | Factor Analysis, Statistical | 1 | 2009 | 293 | 0.020 |
Why?
| | Prednisolone | 1 | 1988 | 66 | 0.020 |
Why?
| | Foreign Bodies | 1 | 2009 | 107 | 0.020 |
Why?
| | Mucositis | 1 | 2008 | 20 | 0.020 |
Why?
| | Methods | 1 | 1988 | 69 | 0.020 |
Why?
| | Chromatography, Liquid | 1 | 2010 | 454 | 0.020 |
Why?
| | Hot Temperature | 1 | 1991 | 407 | 0.020 |
Why?
| | Orbital Diseases | 1 | 1988 | 35 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2013 | 1217 | 0.020 |
Why?
| | Blindness | 1 | 1988 | 52 | 0.020 |
Why?
| | Air | 1 | 1988 | 45 | 0.020 |
Why?
| | Lymphocyte Subsets | 1 | 2008 | 83 | 0.020 |
Why?
| | Silicones | 1 | 2008 | 29 | 0.020 |
Why?
| | Polyethylenes | 1 | 2008 | 11 | 0.020 |
Why?
| | Equipment Design | 1 | 2010 | 530 | 0.020 |
Why?
| | Vasculitis | 1 | 1988 | 69 | 0.020 |
Why?
| | Polytetrafluoroethylene | 1 | 2008 | 25 | 0.020 |
Why?
| | Purine-Nucleoside Phosphorylase | 1 | 2007 | 6 | 0.020 |
Why?
| | Membrane Cofactor Protein | 1 | 2007 | 14 | 0.020 |
Why?
| | Pneumonia | 1 | 2014 | 631 | 0.020 |
Why?
| | Sequence Deletion | 1 | 2008 | 193 | 0.020 |
Why?
| | Up-Regulation | 1 | 2011 | 851 | 0.020 |
Why?
| | Vitreous Hemorrhage | 1 | 1987 | 10 | 0.020 |
Why?
| | Leukocytes, Mononuclear | 1 | 2010 | 573 | 0.020 |
Why?
| | Timolol | 1 | 1987 | 14 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2011 | 824 | 0.020 |
Why?
| | Pilocarpine | 1 | 1987 | 16 | 0.020 |
Why?
| | Ifosfamide | 1 | 2007 | 38 | 0.020 |
Why?
| | Infant, Low Birth Weight | 1 | 2008 | 153 | 0.020 |
Why?
| | Infant, Newborn | 2 | 2010 | 6429 | 0.020 |
Why?
| | Gene Rearrangement | 1 | 2008 | 155 | 0.020 |
Why?
| | Drug Therapy | 1 | 2007 | 80 | 0.020 |
Why?
| | Lymph Nodes | 1 | 2010 | 502 | 0.020 |
Why?
| | Prodrugs | 1 | 2007 | 52 | 0.020 |
Why?
| | Adrenal Cortex Hormones | 1 | 2010 | 478 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2010 | 928 | 0.020 |
Why?
| | Tandem Mass Spectrometry | 1 | 2010 | 576 | 0.020 |
Why?
| | RNA-Binding Proteins | 1 | 2011 | 462 | 0.020 |
Why?
| | Pain Measurement | 1 | 2009 | 552 | 0.020 |
Why?
| | Carboplatin | 1 | 2007 | 160 | 0.020 |
Why?
| | Birth Weight | 1 | 2010 | 522 | 0.020 |
Why?
| | Cerebral Hemorrhage | 1 | 2007 | 120 | 0.020 |
Why?
| | Trabeculectomy | 1 | 1987 | 75 | 0.020 |
Why?
| | Cell Growth Processes | 1 | 2006 | 50 | 0.020 |
Why?
| | Prostheses and Implants | 1 | 2008 | 141 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 1989 | 688 | 0.020 |
Why?
| | Legislation as Topic | 1 | 1986 | 5 | 0.020 |
Why?
| | Gestational Age | 1 | 2010 | 975 | 0.020 |
Why?
| | Injections | 1 | 2007 | 196 | 0.020 |
Why?
| | Immunocompetence | 1 | 2006 | 47 | 0.020 |
Why?
| | Enteral Nutrition | 1 | 2008 | 216 | 0.010 |
Why?
| | Epidemiologic Methods | 1 | 2006 | 89 | 0.010 |
Why?
| | Choroid Neoplasms | 1 | 1986 | 9 | 0.010 |
Why?
| | Mice | 3 | 2010 | 18339 | 0.010 |
Why?
| | Comorbidity | 1 | 2011 | 1658 | 0.010 |
Why?
| | Phenotype | 1 | 2014 | 3162 | 0.010 |
Why?
| | Stress, Mechanical | 1 | 1988 | 494 | 0.010 |
Why?
| | Rabbits | 1 | 2007 | 648 | 0.010 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2010 | 428 | 0.010 |
Why?
| | Gene Silencing | 1 | 2006 | 205 | 0.010 |
Why?
| | Tritium | 1 | 2005 | 68 | 0.010 |
Why?
| | Imaging, Three-Dimensional | 1 | 2009 | 583 | 0.010 |
Why?
| | Myelin Basic Protein | 1 | 2005 | 44 | 0.010 |
Why?
| | Thymidine | 1 | 2005 | 60 | 0.010 |
Why?
| | Nestin | 1 | 2005 | 19 | 0.010 |
Why?
| | Bromodeoxyuridine | 1 | 2005 | 79 | 0.010 |
Why?
| | Intermediate Filament Proteins | 1 | 2005 | 57 | 0.010 |
Why?
| | Accidents, Traffic | 1 | 1986 | 190 | 0.010 |
Why?
| | Pregnancy | 2 | 2010 | 7190 | 0.010 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2005 | 124 | 0.010 |
Why?
| | RNA Interference | 1 | 2006 | 476 | 0.010 |
Why?
| | Transcriptional Activation | 1 | 2006 | 383 | 0.010 |
Why?
| | Embryo, Mammalian | 1 | 2005 | 232 | 0.010 |
Why?
| | Genome-Wide Association Study | 1 | 2011 | 1406 | 0.010 |
Why?
| | Microtubule-Associated Proteins | 1 | 2005 | 196 | 0.010 |
Why?
| | Software | 1 | 2009 | 690 | 0.010 |
Why?
| | Cannabis | 1 | 2011 | 509 | 0.010 |
Why?
| | Adenoviridae Infections | 3 | 1958 | 20 | 0.010 |
Why?
| | Infant, Premature | 1 | 2008 | 611 | 0.010 |
Why?
| | Biocompatible Materials | 1 | 2008 | 435 | 0.010 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 983 | 0.010 |
Why?
| | Length of Stay | 1 | 2008 | 1337 | 0.010 |
Why?
| | Mice, Transgenic | 1 | 2007 | 2182 | 0.010 |
Why?
| | Bed Rest | 1 | 1981 | 15 | 0.010 |
Why?
| | Pediatrics | 1 | 2010 | 1114 | 0.010 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2002 | 105 | 0.010 |
Why?
| | Recovery of Function | 1 | 2006 | 707 | 0.010 |
Why?
| | Immobilization | 1 | 1981 | 53 | 0.010 |
Why?
| | Bupivacaine | 1 | 1981 | 38 | 0.010 |
Why?
| | Joints | 1 | 1982 | 107 | 0.010 |
Why?
| | Colectomy | 1 | 2002 | 107 | 0.010 |
Why?
| | Nerve Tissue Proteins | 1 | 2005 | 592 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2011 | 4557 | 0.010 |
Why?
| | Hypertension | 1 | 2009 | 1263 | 0.010 |
Why?
| | Oculomotor Muscles | 1 | 1981 | 84 | 0.010 |
Why?
| | Suture Techniques | 1 | 1981 | 131 | 0.010 |
Why?
| | Adenoviridae | 2 | 1958 | 199 | 0.010 |
Why?
| | Movement | 1 | 1982 | 293 | 0.010 |
Why?
| | Light Coagulation | 1 | 1980 | 10 | 0.010 |
Why?
| | Gene Expression | 1 | 2005 | 1490 | 0.010 |
Why?
| | HeLa Cells | 2 | 1958 | 650 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2005 | 2527 | 0.010 |
Why?
| | Preoperative Care | 1 | 1981 | 379 | 0.010 |
Why?
| | Emergency Service, Hospital | 1 | 2009 | 2310 | 0.010 |
Why?
| | Diabetic Retinopathy | 1 | 1980 | 208 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2005 | 2832 | 0.010 |
Why?
| | Cryotherapy | 1 | 1996 | 21 | 0.010 |
Why?
| | Laser Coagulation | 1 | 1996 | 77 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2005 | 5992 | 0.010 |
Why?
| | Diabetes Mellitus | 1 | 1982 | 1098 | 0.010 |
Why?
| | Polyarteritis Nodosa | 1 | 1988 | 11 | 0.000 |
Why?
| | Virus Diseases | 2 | 1956 | 216 | 0.000 |
Why?
| | Kidney Failure, Chronic | 1 | 1988 | 598 | 0.000 |
Why?
| | Hand | 1 | 1982 | 161 | 0.000 |
Why?
| | Adenovirus Vaccines | 1 | 1958 | 2 | 0.000 |
Why?
| | Models, Biological | 1 | 1986 | 1821 | 0.000 |
Why?
| | Neutralization Tests | 1 | 1956 | 76 | 0.000 |
Why?
| | Antibody Formation | 1 | 1956 | 294 | 0.000 |
Why?
| | Viruses | 1 | 1956 | 165 | 0.000 |
Why?
| | Cell Culture Techniques | 1 | 1956 | 375 | 0.000 |
Why?
|
|
Johnston's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|